Samsung Bioepis Co., Ltd. is a South Korean biopharmaceutical company headquartered in Incheon, South Korea, focused on developing and manufacturing high-quality biosimilars. While primarily known for biosimilars in immunology and oncology, the company has expanded into neuroscience including neurodegenerative diseases.
Company Overview
| Attribute | Value | |-----------|-------| | Founded | 2012 | | Headquarters | Incheon, South Korea | | Parent | Samsung Biologics (Samsung C&T) | | Stock | KRX: 321550K | | CEO | Christopher Hansung Ko |
Neurodegeneration Pipeline
Alzheimer's Disease Programs
| Drug | Mechanism | Stage | Status | |------|-----------|-------|--------| | SB-303 | Anti-[amyloid beta](/proteins/amyloid-beta) biosimilar | Preclinical | Research | | SB-309 | Anti-[tau](/proteins/tau) antibody biosimilar | Discovery | Early research |
Parkinson's Disease Research
| Drug | Mechanism | Stage | Status | |------|-----------|-------|--------| | SB-401 | [Alpha-synuclein](/proteins/alpha-synuclein) targeting | Discovery | Early research |
Business Model
Samsung Bioepis operates through:
Biosimilar Development: Developing high-quality biosimilars for global markets
Contract Manufacturing: Manufacturing biologic drugs for pharmaceutical partners
Novel Drug Discovery: Expanding into novel drug development for unmet medical needs
Global Partnerships
...
Overview
Samsung Bioepis Co., Ltd. is a South Korean biopharmaceutical company headquartered in Incheon, South Korea, focused on developing and manufacturing high-quality biosimilars. While primarily known for biosimilars in immunology and oncology, the company has expanded into neuroscience including neurodegenerative diseases.
Company Overview
| Attribute | Value | |-----------|-------| | Founded | 2012 | | Headquarters | Incheon, South Korea | | Parent | Samsung Biologics (Samsung C&T) | | Stock | KRX: 321550K | | CEO | Christopher Hansung Ko |
Neurodegeneration Pipeline
Alzheimer's Disease Programs
| Drug | Mechanism | Stage | Status | |------|-----------|-------|--------| | SB-303 | Anti-[amyloid beta](/proteins/amyloid-beta) biosimilar | Preclinical | Research | | SB-309 | Anti-[tau](/proteins/tau) antibody biosimilar | Discovery | Early research |
Parkinson's Disease Research
| Drug | Mechanism | Stage | Status | |------|-----------|-------|--------| | SB-401 | [Alpha-synuclein](/proteins/alpha-synuclein) targeting | Discovery | Early research |
Business Model
Samsung Bioepis operates through:
Biosimilar Development: Developing high-quality biosimilars for global markets
Contract Manufacturing: Manufacturing biologic drugs for pharmaceutical partners
Novel Drug Discovery: Expanding into novel drug development for unmet medical needs
Global Partnerships
Bristol Myers Squibb: Partnership for biosimilar development (ended)
Biogen: Partnership for immunology biosimilars
Samsung Biologics: Manufacturing infrastructure
Strategic Importance for Neurodegeneration
Samsung Bioepis represents a significant player in making biologic therapies accessible:
Biosimilar cost reduction: Biosimilars typically cost 15-30% less than reference biologics
Manufacturing scale: Samsung Biologics' massive manufacturing capacity enables global supply
Regulatory expertise: Experience navigating FDA, EMA, and Korean regulatory pathways
Cold chain capabilities: Advanced capabilities for temperature-sensitive biologic products
Future Pipeline
Samsung Bioepis has announced expansion into neurodegenerative diseases: